杨露
杨露，实验师，硕士生导师，药剂学硕士、中药药理学博士。主要从事中药/民族药药理机制及纳米递药系统研究。主持国家自然科学青年基金、四川省自然科学青年基金、立即博备用网址_立即博赌场-游戏平台“杏林学者”人才提升计划项目共3项，参与国家自然科学基金面上项目、四川省科技厅面上项目等多项。在国内外期刊发表学术论文20余篇，包括Small、ACS Applied Materials & Interfaces、Journal of Ethnopharmacology、Biomedicine & Pharmacotherapy、Chinese Chemical Letters、International Journal of Nanomedicine等领域内主流杂志，为ACS Applied Materials & Interfaces、Phytomedicine、Journal of Ethnopharmacology等期刊审稿人。
联系方式：yangluyl@cdutcm.edu.cn，18381095021
代表性成果
（一）承担项目
1. 国家自然科学基金青年基金，82304880，2024.01-2026.12，主持
2. 四川省自然科学基金青年基金，2023NSFSC1782，2023.01-2024.12，主持
3. 立即博备用网址_立即博赌场-游戏平台“杏林学者”人才提升计划项目，2023NSFSC3244，2023.11-2025.10，主持
（二）发表论文
1.Lu Yang, Xianfeng Liu, Siyin Chen, Jiayi Sun, Yiwen Tao, liyuan Ma, Yong Zeng, Kaipei Luo*, Ruimin Tian*, Xianli Meng*. Scutellarin Ameliorates Mitochondrial Dysfunction and Apoptosis in OGD/R-Insulted HT22 Cells through Mitophagy Induction. Biomedicine & Pharmacotherapy, 2024, 179: 117340.（IF: 6.9，中科院二区）
2.Lu Yang, Yiwen Tao, Liuling Luo, Yi Zhang*, Xiaobo Wang*, Xianli Meng*. Dengzhan Xixin injection derived from a traditional Chinese herb Erigeron breviscapus ameliorates cerebral ischemia/reperfusion injury in rats via modulation of mitophagy and mitochondrial apoptosis. Journal of Ethnopharmacology, 2022, 288, 114988.（IF: 5.4，中科院二区）
3.Kaipei Luo#*, Lu Yang#, Chunmei Yan, Yuxin Zhao, Qiuxia Li, Xing Liu, Long Xie, Qiang Sun, Xiaofang Li*. A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation. Small, 2023, 19: 2302834.（IF: 13.3，中科院一区，封面论文）
4.Chunmei Yan, Yuxin Zhao, Xiaolian Liu, Yingjie Jiang, Qiuxia Li, Lu Yang*, Xiaofang Li*, Kaipei Luo*. Self-delivery Nano-booster to Enhance Immunogenic Cell Death for Cancer Chemoimmunotherapy. ACS Applied Materials & Interfaces, 2024, 16: 33169-33181.（IF: 9.5，中科院二区）
5.Ruimin Tian, Xianfeng Liu, Yang Xiao, Lijia Jing, Honglin Tao, Lu Yang*, Xianli Meng*. Huang-Lian-Jie-Du decoction drug-containing serum inhibits IL-1β secretion from D-glucose and PA induced BV2 cells via autophagy/NLRP3 signaling. Journal of Ethnopharmacology, 2024, 323, 117686.（IF: 4.8，中科院二区）
6.Yingjie Jiang, Chunmei Yan, Minghao Li, Siying Chen, Zhimin Chen*, Lu Yang*, Kaipei Luo*. Delivery of natural products via polysaccharide-based nanocarriers for cancer therapy: A review on recent advances and future challenges. International Journal of Biological Macromolecules, 2024, 278: 135072.（IF: 7.7，中科院一区）
7.Fangfang Fan#, Lu Yang#, Rui Li, Xuemei Zou, Ning Li, Xianli Meng*, Yi Zhang*, Xiaobo Wang*. Salidroside as a potential neuroprotective agent for ischemic stroke: a review of sources, pharmacokinetics, mechanism and safety. Biomedicine & Pharmacotherapy, 2020, 129: 110458. (IF：7.42，中科院二区)
8.Yiwen Tao#, Lu Yang#, Shiyu Chen, et al. Pivotal regulatory roles of traditional Chinese medicine in ischemic stroke via inhibition of NLRP3 inflammasome. Journal of Ethnopharmacology, 2022, 294, 115316.（IF: 5.4，中科院二区）
9.Jiayi Sun, Jingyang Li, Xi Li, Lu Yang, Yitong Liu, Huile Gao*, Li Xiang*. Sequentially responsive size reduction and drug release of core-satellite nanoparticles to enhance tumor penetration and effective tumor suppression. Chinese Chemical Letters, 2023, 34(5), 107891.（IF: 9.1，中科院一区）
10.Shengnan Jiang, Fangfang Fan, Lu Yang, Ke Chen, Zhihao Sun, Yi Zhang, Nanjia Cairang, Xiaobo Wang*, Xianli Meng*. Salidroside attenuates high altitude hypobaric hypoxia-induced brain injury in mice via inhibiting NF-κB/NLRP3 pathway. European Journal of Pharmacology, 2022, 15, 175015.（IF: 5.1，中科院三区）